NCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Lokon Pharma AB
TILT Biotherapeutics Ltd.
GeoVax, Inc.
Orca Therapeutics B.V.
AlloVir
Panacela Labs LLC